

Robert E. Lee, MD, FACS Echelon Development Group, LLC

**ECHELON** 

## Disclosures


- I was a full time employee of the US FDA until retiring on 9/30/2024
- Current principal, Echelon Development
- No commercial conflicts relative to this presentation


**ECHELON** 


## **Device Labeling**

- Indications for Use
- Adequate Operating Instructions
- Expected Risks / Benefits
- Contraindications: risks outweigh the benefits
- Warnings : death or serious injury
- Precautions: minor or moderate injury

*ECHELON* 







*ECHELON* 

A feasimistic disidely acceptable effectiveness, the property effectiveness framework and the A lower. The P is a lower hap provide p		SSED: Best concise information source on device	
	CONTRAT <sup>IN</sup> Group	PTA Group	
Total number of access circuit reinterventions	226	242	performance
Total number of target lesion reinterventions	93	195	periormalice
Total number of reinterventions for new lesions in the access circuit	142	98	
Number of subjects requiring access circuit reinterventions Number of subjects requiring target lesion reinterventions	100	102	
Number of subjects requiring target lesion remerventions Number of subjects with reinterventions for new lesions in the access			
circuit	75	49	
While the total number of reinterventions for acco considerable reduction in the number of reinterv treatment with COVERA <sup>TM</sup> Vascular Covered Stern more reinterventions for new lesions in the ac COVERA <sup>TM</sup> treated group compared to the PTA a	entions for the targ compared to PTA a cess circuit were to	et lesions after done. However, required in the	

MAUDE



Medical Device Safety Communications present FDA's analysis of a current safety issue and provide specific regulatory approaches and clinical recommendations for patient management.

**ECHELON** 

ce allows you to receive important FDA news and sign up, please select the topics that interest you To subscribe, all you need is a valid e-mail address. Your e-mail will only be used to deliver the requested information or to give you access to your subscription preferen Visit <u>FDA's privacy policy</u> for more details.

Check for updates

ns 🕑

#### The Long-Term EVAR Assessment and Follow-Up (LEAF) System **LEAF Objectives** · Industry sponsored initiative Arose from the 2021 FDA Accurately Measure Long-Term endograft panels that pointed Post-EVAR Outcomes: out the need for long term Survival device specific EVAR follow-Reintervention up. Late AAA rupture · Led by Dr. Phil Goodney


**ECHELON** 



### PRACTICE MANAGEMENT

The Vascular Implant Surveillance and Interventional Outcomes (VISION) Coordinated Registry Network: An effort to advance evidence evaluation for vascular devices

Vasculard Letrucks<sup>1</sup><sup>1</sup> and Klinup Jorgensen, MD<sup>2</sup> Daniel Bertges, MD<sup>2</sup> Marc Schermerhorn, MD<sup>2</sup> Pablo Merale, MD<sup>2</sup> Scott Williams, MS, RAC<sup>2</sup>, Roberta Block, MS<sup>2</sup> Jealed Sainors, MD, MH<sup>1</sup> Sain E. Deery MD<sup>2</sup> Scott Williams, MS, RAC<sup>2</sup>, Roberta Block, MS<sup>2</sup> Sections, MD, MH<sup>1</sup> Marchael MD<sup>2</sup>, MD<sup></sup>



# FDA DEVICE RESOURCE LINKS

• <u>PMA Database</u> • <u>510(k) Database</u>

- <u>S101K1 Database</u>
  <u>DeNovo Database</u>
  <u>MAUDE Database</u>
  <u>Medical Product Safety Network</u>
  <u>Medical Device Recalls</u>
  <u>522 Post-market Surveillance Studies Database</u>
  <u>Letters to Health Care Providers</u>

- Safety Communications
  Subscribe to FDA Email Notifications

*ECHELON*